Asthma Clinical Trial
Official title:
Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator in the Treatment of Patients With Obstructive Pulmonary Disease
Aerosol therapy is widely used in intensive care in critically ill patients that use mechanical ventilation (MV). However, there is a lack of standardization about aerosol performance in this group of patients. Thus, this study aims to evaluate the effect of nebulization performed in different ventilatory modes on lung function and regional pulmonary distribution of critical patients with chronic obstructive pulmonary disease. It is a clinical trial, crossover, randomized, controlled and blind. Three interventions with bronchodilators will be performed: in the Pressure Controlled Ventilation mode (PCV) with positive end expiratory pressure (PEEP) = 85% of autoPEEP, in the PCV mode with PEEP = 15 cmH2Oand in the Pressure Support Mode (PSV). Pulmonary function data will be evaluated through Electrical Impedance Tomography to evaluate the efficacy of the bronchodilator in different ventilatory modes.
2. OBJECTIVES
2.1 Primary
• To evaluate the influence of mechanical ventilation modes in the efficacy of nebulized
bronchodilator in ventilator dependent patients with obstructive pulmonary disease.
2.2 Secondary
- To compare regional ventilation distribution through Ventilation Surface Area (VSA) and
Tidal Impedance Variation (TIV or ∆Z) by electrical impedance tomography (EIT) before,
immediately after, after 1hour (h), 2h and 3h of nebulized bronchodilator in pressure
controlled ventilation (PCV) with and without sedative drugs, and during pressure
support ventilation (PSV).
- To compare the peak expiratory flow (PEF), change in End-Expiratory Lung Volume (dEELV),
Respiratory Compliance (Crs) and Resistance (R), before, immediately after, after 1h, 2h
and 3h of nebulized bronchodilator by monitoring airway pressure and EIT in ventilator
modes PCV, with and without sedative drugs and PSV .
- To compare the ventilator modes on the VSA, ∆Z, PEF, dEELV and Crs after nebulized
bronchodilator and the duration of its effects during mechanical ventilation.
- To compare two different level of PEEP during nebulized bronchodilator on PCV mode while
the patient stay with sedative drugs.
3. METHODS
3.1 Study design This is a randomized crossover, blinded clinical trial. The randomization
procedure will be a simple randomization by random number table. In order to improve
reliability, not transparent sealed envelopes for blind allocation will be used.
3.2 Local and study period This is a multicenter study that involve the following hospitals:
Hospital Miguel Arraes - PE and Real Hospital Português de Beneficência em Pernambuco- PE.
All hospitals are located in the metropolitan region of Recife, Pernambuco, Brazil and the
study will be conducted from February 2016 to December 2019.
3.3 Sample The study population consist of patients with obstructive pulmonary disease
admitted to intensive care unit for MV support who meet the inclusion criteria.
3.4 Sample size Patients will be identified by a daily telephone calls to the ICUs each
morning for data collection. Potential candidate patients will be screened for inclusion and
exclusinon criteria, after the identification of eligible patients. After consent is
obtained, the research team goes to the ICU to start collecting data. The sample size will be
calculated by statistical procedures after conducting a pilot study of 10 patients.
3.5 Technical procedures and tools for data collection
Prior to starting the intervention, clinical and demographic data will be collected according
to the evaluation form, ( Appendix 2). After that, patients will be receive each of 4
interventions, with a minimum of 4 hours between bronchodilator administration to allow for
washout.
3.5.1. Intervention Protocol 3.5.1.1. Step 1: Nebulization during Pressure Controlled
Ventilation (PCV) Mode Initially the patient will be accessed when he still sedated. Two
intervention will be done with a PCV mode in two different ways and the order of the
procedures will be randomized.
One nebulization will be done with a standard PCV mode and parameters will be setted as
follows: sufficient Δ pressure to maintain the patient's tidal volume (vt) at 6 / kg ideal
weight, respiratory rate (RR) at 12 bpm, inspiratory time (Ti) up to 1 second, maintain Ti /
Ttot 0.3 - 0.4 without causing dynamic AutoPEEP, decreasing waveform flow and PEEP level of
85% from static autoPEEP.
Other nebulization will be done also in PCV mode with same parameters, but the level of PEEP
will be increased to 15 cmH2O. Between this two interventions will be given 4 hours for
washout.
After this, we will talk to the medical staff to interrupt sedation, will be given 3 hour for
wash out to start de Step 2.
3.5.1.2. Step 2: Nebulization During Pressure Support Ventilation (PSV) With a clinical
progression of the patient, a 4th evaluation will be done on the first day when the patient
achieve PSV mode. In this ventilation mode the patient will control the Ti, Ttot, RR and
inspiratory flow so it will be set only one Δ pressure for the patient to support a Vt of 6
ml/kg. The lowest minimum value of Δ P is 10 cmH2O and the end of inspiratory phase will be
determined by a decrease at 25% of the patient peak inspiratory flow.
3.5.2 Nebulization Protocol
Nebulized bronchodilator drugs will be Salbutamol Sulfate (aerolin nebulis) and ipratropium
bromide (atrovent) diluted in a saline solution (saline 0.9%) in 3 ml. The vibrating Mesh
nebulizer (Aeroneb Pro-X, Galway, Ireland) will be placed in the inspiratory circuit of the
MV immediately before 'Y' piece using a 22 mm T adapter. The nebulizer is operated by an
electric controller connected mains power. The vibrating Mesh produces aerosol with an
average particle size of 5 μm and will remain on continuously until the end of nebulization.
If a heat moisture exchanger (HME) is used during mechanical ventilation, it must be removed
from between the nebulizer and airway before nebulization so that it does not filter out and
reduce aerosol delivered.
3.5.3 Evaluation by Electrical Impedance Tomography. TIE is a tool of obtaining transverse
plane image of any section of the human body by means of low-power electric current. The
image is obtained from the electric current or potential detected on the surface of the
evaluated area, where each "pixel" image is its impedance or resistivity. Thus, when used in
thoracic follow-up, the EIT is able to evaluate the aeration and ventilation of the patient
through the following variables: distribution of regional lung ventilation by Tidal Impedance
Variation (ΔZ), Ventilation Surface Area (VSA), Percentage of Recruitable Lung (PRLV), Change
in End-Expiratory Lung Volume (dEELV) and Respiratory Compliance (Crs) .
Initially, to evaluate the acute pulmonary impact of nebulizer bronchodilator on different
ventilatory modes, EIT will be be performed before and immediately after the aerosol
administration and repeated with each ventilation mode. Furthermore, the duration of
nebulization effect will be evaluated by performing EIT after 1, 2 and 3h in each ventilation
mode. There will be a > 4 hour washout between bronchodilator administrations.
An impedance tomography (ENLIGHTER, Timpel, Brazil) will be used with the patient in supine
position with a bed elevation of 45◦, so a belt with 32 electrodes will be applied to the
chest, in the position corresponding to the 4th - 5th intercostal space on a shaved skin.
Electrodes have to be positioned for reading electrocardiograms and a flow sensor that should
be attached to the endotracheal tube. After this procedures recording data starts for 3
minutes.
For image acquisition, harmless electrical currents (5-8 nA, 125 KHz) will be injectates
through electrode pairs in rotating sequence, and the potential differences Will be captured
in other non injetantes electrode. Variations in thoracic impedance will be evaluated through
a LabView software (National Instruments, USA) and the data is recorded in separate files for
patients for further analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|